Current Trends and Future Directions in the Treatment of Advanced Urological Cancers

Dear Colleagues,

The Journal of Clinical Medicine announces a new Special Issue “Current Trends and Future Directions in the Treatment of Advanced Urological Cancers”.

Advanced urological malignancies comprise a diverse group of cancers including bladder, prostate and kidney cancer, each posing unique therapeutic challenges Bladder cancer remains an aggressive tumor with poor outcomes; recent advances for metastatic BC, such as the combination of Immune Checkpoint Inhibitors (ICIs) and Antibody Drug Conjugates, are changing the therapeutic landscape, but adverse events and patient selection remain an issue.

In metastatic renal cell carcinoma, ICIs significantly changed first line treatment; however, management after progression remains unclear, highlighting the need for new therapeutic strategies. Recent developments such as the characterization of Hypoxia-Induced Factor-1 are promising but more data are needed to inform trials and clinical decisions.

In prostate cancer, practice-changing advances in the treatment of localized, hormone sensitive tumors are not reflected in metastatic, castration-resistant disease (mCRPC); new therapeutic tools such as the PSMA-lutetium scan and ICIs have been introduced, alongside genetic features such as Mismatch Repair and Microsatellite Instability, bringing insight into different patient populations with diverse cancer subtypes.

The aim of this Special Issue is to provide new insights and data on the therapeutic management of advanced urological malignancies.

Dr. Dimitrios Makrakis
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• checkpoint inhibitors
• advanced bladder cancer
• bladder cancer histological variants
• metastatic RCC
• castration-resistant prostate cancer
• prostate cancer immunotherapy